CVAC - Pendapatan operasional sadurunge ngurangi amortisasi CureVac

A stable staff of RNA experts minimizes personnel risks, supporting the dynamics of EBITDA, which currently stands at approximately 0.00 for CureVac N.V. (CVAC). The business foundation is based on B2B/B2G supplies of mRNA therapies, while the development of thermostable drugs optimizes logistics costs. This chart visualizes the consolidation phases of cash flows from operating activities before taxes.

CVAC - Bathi operasional sadurunge ngurangi amortisasi CureVac Corp ing rentang 23.11.2025 - 17.01.2026

CureVac (CVAC) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:

Bagan rega CureVac Pharma|CVAC - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Kapitalisasi pasar CureVac|CVAC - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Nilai Akuntansi Saham CureVac|CVAC - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku curevac.com|CVAC - Aset Agregat Perusahaan

- data tingkat utang lan likuiditas finansial:

Koefisien Total Utang marang Modal CureVac N.V.|CVAC - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas CureVac NV|CVAC - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku CureVac|CVAC - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan CureVac|Likuiditas darurat curevac.com

- statistik bathi lan rasio pasar:

CVAC - Penghasilan resik|Bathi sing dikarepake CureVac N.V.|CVAC - Pangali P/E|Pangali Forward P/E curevac.com|CVAC - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CureVac|CVAC - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku CureVac|CVAC - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan curevac.com|CVAC - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep CureVac N.V.

Pambiji fundamental perusahaan:CVAC (CureVac Pharma)

High costs associated with recruiting elite German mRNA scientists directly impact the operational efficiency of CureVac N.V. (CVAC). This metric measures actual cash flow from core operations minus production costs. It determines the business's ability to maintain its scientific foundation without external borrowing. A sharp decline in these values signals a risk of capital freeze. By analyzing quarterly EBITDA, investors assess the company's resilience to market volatility.

Pesaing CureVac N.V. (CVAC)

Gilead Corp - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Cidara Therapeutics, Inc. - Bathi operasional EBITDA|Pendapatan operasional sadurunge ngurangi amortisasi novavax.com NVAX|Valneva (VALN) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Vir Biotechnology Inc - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional sadurunge ngurangi amortisasi SIGA|Bathi operasional EBITDA Emergent Bio|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Atea Pharmaceuticals (AVIR)|Pendapatan operasional sadurunge ngurangi amortisasi invivyd.com|Bathi operasional EBITDA ENTA (Enanta Pharmaceuticals, Inc.)|INO - Bathi operasional sadurunge ngurangi amortisasi|HLVX: Bathi operasional sadurunge ngurangi amortisasi|KLRS - Bathi operasional EBITDA|dyadic.com (DYAI) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|NanoViricides - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|TLPH (Talphera) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Cocrystal Pharma Inc COCP|Bathi operasional sadurunge ngurangi amortisasi TRAW (Traws Pharma, Inc.)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi DWTX (dwtx.com)|Bathi operasional EBITDA QLGN (Qualigen Therapeutics)|Bathi operasional EBITDA AlloVir Inc ALVR|VBI Vaccines Inc - Bathi operasional EBITDA|Virios Therapeutics (VIRI) - Bathi operasional sadurunge ngurangi amortisasi|VXRT (vaxart.com) - Bathi operasional sadurunge ngurangi amortisasi